Payment overview · 2025
General Payments
$730.38
36 reported records · 13 companies
Healthcare provider profile · identity verified
Brittany Bobrowski, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · BOONEVILLE, KY · NPI 1871900795
Verified facts
What the public records show
CMS Open Payments records show Brittany Bobrowski, D.O. received $730.38 in general payments during 2025 across 36 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 19.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Eliquis, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $145.29 | 19.9% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $141.53 | 19.4% | 7 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $81.07 | 11.1% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $61.82 | 8.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $61.35 | 8.4% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.62 | 6.4% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $40.07 | 5.5% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $34.85 | 4.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.83 | 4.4% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $28.38 | 3.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.79 | 2.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $19.58 | 2.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.20 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $730.38 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $145.29 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $94.19 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $84.61 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $81.07 | 3 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $81.07 | 3 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $61.82 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $61.35 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $61.35 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $46.62 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $40.07 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $34.85 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $31.83 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.77 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $28.38 | 1 | 2025 |
Source payment records
|
|||||
| SPEVIGO Normalized: spevigo |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $19.58 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 102 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 90 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
39 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
104 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
104 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
90 | 17 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
102 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
28 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 830 | 115 |
| Gabapentin | Gabapentin | 613 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 566 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 481 | 99 |
| Montelukast Sodium | Montelukast Sodium | 456 | 93 |
| Omeprazole | Omeprazole | 456 | 96 |
| Lisinopril | Lisinopril | 449 | 98 |
| Atorvastatin Calcium | Atorvastatin Calcium | 330 | 87 |
| Metformin Hcl | Metformin Hcl | 311 | 70 |
| Losartan Potassium | Losartan Potassium | 288 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 276 | 56 |
| Diazepam | Diazepam | 270 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 268 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 256 | 67 |
| Furosemide | Furosemide | 235 | 65 |
| Potassium Chloride | Potassium Chloride | 232 | 70 |
| Ozempic | Semaglutide | 229 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 223 | 66 |
| Celecoxib | Celecoxib | 198 | 47 |
| Ropinirole Hcl | Ropinirole Hcl | 196 | 33 |
| Clonazepam | Clonazepam | 192 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 185 | 45 |
| Glipizide | Glipizide | 182 | 32 |
| Trazodone Hcl | Trazodone Hcl | 180 | 38 |
| Sertraline Hcl | Sertraline Hcl | 175 | 44 |
| Simvastatin | Simvastatin | 171 | 37 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 168 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 159 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 56 |
| Januvia | Sitagliptin Phosphate | 149 | 32 |
| Ibuprofen | Ibuprofen | 146 | 37 |
| Ondansetron Odt | Ondansetron | 145 | 44 |
| Ventolin Hfa | Albuterol Sulfate | 142 | 39 |
| Levofloxacin | Levofloxacin | 138 | 97 |
| Prednisone | Prednisone | 135 | 77 |
| Ezetimibe | Ezetimibe | 127 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 126 | 35 |
| Carvedilol | Carvedilol | 122 | 22 |
| Alendronate Sodium | Alendronate Sodium | 120 | 20 |
| Alprazolam | Alprazolam | 110 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 109 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 27 |
| Meloxicam | Meloxicam | 109 | 32 |
| Jardiance | Empagliflozin | 104 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 23 |
| Eliquis | Apixaban | 102 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 102 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 96 | 36 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 93 | 17 |
| Azithromycin | Azithromycin | 92 | 68 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 92 | 12 |
| Atenolol | Atenolol | 91 | 19 |
| Fluconazole | Fluconazole | 91 | 41 |
| Mounjaro | Tirzepatide | 90 | 17 |
| Spironolactone | Spironolactone | 90 | 21 |
| Pregabalin | Pregabalin | 89 | 20 |
| Buspirone Hcl | Buspirone Hcl | 84 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 80 | 16 |
| Lorazepam | Lorazepam | 79 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 17 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 67 | 12 |
| Meclizine Hcl | Meclizine Hcl | 67 | 26 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 67 | 11 |
| Famotidine | Famotidine | 66 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 65 | 11 |
| Allopurinol | Allopurinol | 63 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 13 |
| Tramadol Hcl | Tramadol Hcl | 62 | 17 |
| Promethazine Hcl | Promethazine Hcl | 61 | 22 |
| Topiramate | Topiramate | 61 | 11 |
| Methocarbamol | Methocarbamol | 59 | 21 |
| Roflumilast | Roflumilast | 59 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 57 | 12 |
| Fenofibrate | Fenofibrate | 56 | 12 |
| Nifedipine Er | Nifedipine | 53 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 35 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 52 | 41 |
| Farxiga | Dapagliflozin Propanediol | 51 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 50 | 13 |
| Chlorthalidone | Chlorthalidone | 49 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 16 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 47 | suppressed |
| Glipizide Er | Glipizide | 46 | suppressed |
| Estradiol | Estradiol | 45 | 12 |
| Invokana | Canagliflozin | 45 | suppressed |
| Nystatin | Nystatin | 45 | 26 |
| Primidone | Primidone | 45 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 34 |
| Mirtazapine | Mirtazapine | 42 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Amoxicillin | Amoxicillin | 41 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 40 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 39 | 13 |
| Nitroglycerin | Nitroglycerin | 38 | 19 |
| Spiriva Respimat | Tiotropium Bromide | 37 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Verapamil Er | Verapamil Hcl | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Bumetanide | Bumetanide | 35 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | 11 |
| Lovastatin | Lovastatin | 34 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 25 |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 31 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Risperidone | Risperidone | 31 | suppressed |
| Rybelsus | Semaglutide | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 27 |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Cefdinir | Cefdinir | 26 | 23 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 21 |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Premarin | Estrogens, Conjugated | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Ibu | Ibuprofen | 21 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | 12 |
| Febuxostat | Febuxostat | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 17 |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 17 | 17 |
| Prednisolone Acetate | Prednisolone Acetate | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Oxaprozin | Oxaprozin | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Lyllana | Estradiol | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $730.38 · 36 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, Dexcom G6 Transmitter, ELIQUIS, FANAPT, HETLIOZ, Hillrom - Vest System Model 105 Home Care, JOURNAVX, Korlym, LEQVIO, MOUNJARO, NURTEC ODT, SPEVIGO, VRAYLAR, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error